证券代码：603858 证券简称：步长制药 公告编号：2025-094 山东步长制药股份有限公司 关于拟放弃优先受让控股子公司股权暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经友好协商，2025 年 5 月 8 日，各方就本次股权转让中的股权转让价款支付 安排进行补充约定，并正式签署了《四川泸州步长生物制药有限公司股权转让协 议之补充协议》。具体内容详见公司 2025 年 5 月 9 日披露于上海证券交易所网站 （www.sse.com.cn）的《关于拟放弃优先受让控股子公司股权暨关联交易的进展 公告》（公告编号：2025-086）。 二、本次交易的进展 近日，泸州步长已完成工商变更登记手续。变更后的相关信息如下： 名称：四川泸州步长生物制药有限公司 类型：其他有限责任公司 法定代表人：杨春 注册资本：44,000 万元整 成立日期：2014 年 09 月 17 日 住所：四川省泸州市泸县康乐大道西段 480 号 经营范围：许可项目：药品生产；药品批发；药品进出口（依法须经批准的 项目，经相关部门批准 ...

Policy Trends - Recent COVID-19 infections show a slight increase in some regions, but the clinical severity has not changed significantly according to a Chinese CDC expert [2] Drug and Device Approvals - Changshan Pharmaceutical's nadroparin calcium injection has received a drug registration certificate from Belarus, used for treating venous thromboembolism and other related conditions [3] - Shanghai Pharmaceuticals announced that its rivaroxaban tablets have received approval from the US FDA, aimed at reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients, among other uses [4] Capital Markets - Shanghai Kejun Pharmaceutical Technology Co., Ltd. completed a B+ round financing exceeding 100 million yuan, with funds primarily allocated for the phase III clinical development of its core product CG-0255 in the cardiovascular field [5] Industry Developments - Jingyin Pharmaceutical and CRISPR Therapeutics have formed a strategic partnership to jointly develop and commercialize a long-acting siRNA therapy for thrombotic diseases [6] - Buchang Pharmaceutical's subsidiary signed a commissioned research agreement with Fubicheng Pharmaceutical for the development of MF59 adjuvant [7] - Sanofi and Pfizer entered into a licensing agreement for a bispecific antibody product targeting PD-1 and VEGF, with Pfizer gaining exclusive rights outside mainland China [9] Public Sentiment Alerts - Jinhua Co., Ltd. reported that shareholder Xinyu Jinyu has reduced its holdings by 133,500 shares, representing 0.035765% of the company's total share capital [10] - Fosun Pharma announced the resignation of its Senior Vice President Rong Yang for personal reasons, effective May 16, 2025 [11]

Group 1 - Zhaoyi Innovation plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders and market conditions [3] - ST Zhongdi has decided to abandon the commercial opportunity for the Jiageng Ke Yi City land project, with the controlling shareholder planning to develop the project instead [4] - Xichang Electric Power expects a reduction of approximately 5.4 million yuan in net profit for 2025 due to adjustments in the time-of-use electricity pricing mechanism [5] Group 2 - Sanfu New Materials intends to invest 620 million yuan in a project for high-safety dry electrode battery key materials and high-frequency electronic information composite materials [6] - Weifu High-Tech's subsidiary plans to establish a joint venture with Baolong Technology to expand the active suspension motor hydraulic pump business [7] - Yulong Co., Ltd. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [8] Group 3 - Chen'an Technology's shareholder is transferring 6.27% of the company's shares to Hefei Guotou, aiming to introduce strategic investors [9] - Huamao Technology is planning to acquire a 100% stake in Fuchuang Youyue, with stock trading suspended for up to 10 trading days [11] - Baolong Technology's subsidiary will collaborate with Weifu High-Tech's subsidiary to develop core components for the active suspension system [12] Group 4 - Zhongnong Lihua intends to acquire at least 50% of Taizhou Agricultural Supplies, enhancing its product and service range [13] - Weiling Co., Ltd.'s subsidiary has successfully acquired 74.3% of Jiayu Mining for 220 million yuan, focusing on expanding into the non-ferrous metal resource sector [14][15] - Hengshi Technology's subsidiary has been approved for public transfer of shares on the New Third Board [16] Group 5 - Xiang Teng New Materials plans to acquire an additional 12.5% stake in its subsidiary Shanghai Shangda for 25.3 million yuan [17] - ST Texin has extended its employee stock ownership plan by 12 months, reflecting confidence in the company's long-term development [18] - Baili Electric has issued a risk warning regarding its stock price increase, indicating no significant changes in fundamentals [19] Group 6 - Hu Silicon Industry plans to acquire minority stakes in three semiconductor companies for approximately 7.04 billion yuan [20][21] - Demais plans to change its controlling shareholder, leading to a temporary suspension of stock trading [22] - FAW Fuwei has received a notice from a well-known new energy brand for a project expected to generate 1.06 billion yuan in total sales over its lifecycle [23] Group 7 - Hangyang Co. plans to establish a subsidiary for a large modular cryogenic equipment manufacturing project with an estimated investment of 557 million yuan [24] - Jiewate intends to acquire 40.89% of Tianyi Hexin for 319 million yuan, enhancing its product line in the signal chain category [25] - Dingxin Communications has elected a new chairman following the resignation of the previous chairman [26][27] Group 8 - Aofei Entertainment plans to invest 10 million yuan in a partnership to indirectly invest in AI robotics company Xuan Yuan Technology [28] - Huaxi Energy's controlling shareholder has been detained, but the company states that operations remain normal [29] - Yihe Jiaye will change its stock name to "Ruimaite" starting May 21 [30] Group 9 - Zhongjin Environment will change its name to "Southern Pump Industry" effective May 21 [31] - Hong Sifang's subsidiary plans to invest approximately 1.49 billion yuan in a new chemical materials and fertilizers industrial park [32] - Buchang Pharmaceutical's subsidiary has signed a research agreement for MF59 adjuvant with a pharmaceutical company [33] Group 10 - Hongjing Technology has signed a service contract worth 597 million yuan for a smart computing project [34] - Zhuojin Co. has won a bid for a soil remediation project worth 67.68 million yuan [35] - Xinjiang Jiaojian has been awarded a contract for a highway project valued at 451 million yuan [36] Group 11 - China National Materials Energy's subsidiary has signed a contract for an EPC project in Uzbekistan worth approximately 1.252 billion yuan [37] - Ruixin Microelectronics' shareholder plans to reduce its stake by up to 2% [38] - Shanghai Yizhong's shareholder also plans to reduce its stake by up to 2% [39] Group 12 - Sanyou Medical's controlling shareholder plans to reduce its stake by up to 1.44% [40] - Hangdian Co.'s controlling shareholder plans to reduce its stake by up to 1.93% [41] - Shangwei New Materials' shareholder plans to reduce its stake by up to 3% [42] Group 13 - Mingchen Health plans to repurchase shares worth between 30 million and 50 million yuan [43] - Jiuhua Tourism plans to raise up to 500 million yuan through a private placement for various projects [44] - Yuegui Co. plans to raise up to 900 million yuan for several projects [46]

Group 1 - Zhaoyi Innovation plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders and market conditions [3] - ST Zhongdi has decided to abandon the commercial opportunity for the Jiageng Science and Art City land project, which has an area of 108,600 square meters and a starting price of 2.067 billion yuan [4] - Xichang Electric Power expects a reduction of approximately 5.4 million yuan in net profit for 2025 due to adjustments in the time-of-use electricity pricing mechanism [5] Group 2 - Sanfu New Technology plans to invest 620 million yuan in a project for high-safety dry electrode battery key materials and high-frequency electronic information composite materials, with production expected to start in June 2025 [6] - Weifu High-Tech's subsidiary will establish a joint venture with Baolong Technology to expand the business of fully active suspension motor hydraulic pumps, with a registered capital of 400 million yuan [7] - Yulong Co., Ltd. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [8] Group 3 - Chensan Technology's shareholder Shanghai Ruiwei will transfer 14.58 million shares, representing 6.27% of the company, to Hefei Guotou, with the transfer price set at 17.7 yuan per share [10] - Huamao Technology is planning to acquire a 100% stake in Fuchuang Youyue, currently holding 42.16% of the company, with stock trading suspended for up to 10 days [11] - Baolong Technology's subsidiary will partner with Weifu High-Tech's subsidiary to develop and mass-produce core components for fully active suspension systems [12] Group 4 - Buchang Pharmaceutical's subsidiary has signed a commissioned research agreement with Fubicheng Pharmaceutical for the MF59 emulsion adjuvant [14] - Hongjing Technology has signed a service contract worth 597 million yuan for a smart computing project, with a duration of five years [15] - Zhuojin Co., Ltd. has won a bid for a soil remediation project worth 67.68 million yuan, with an expected share of approximately 59.9 million yuan [16] - Xinjiang Jiaojian has been awarded a contract for the G3013 line Ucha to Kangsou highway project, with a bid amount of 451 million yuan [17] Group 5 - Mingchen Health plans to repurchase shares worth between 30 million and 50 million yuan for employee stock ownership plans, with a maximum repurchase price of 23 yuan per share [19]

或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●公司拟将持有的 9 家控股子公司（宁波步长贸易、山东步长药妆、山东步 长鼎晟、山东步长传方、山东步长优品、济南步长驰骋、济南步长财淦、济南步 长瀛玺、济南步长众福）各 1%股权转让给谢继辉。 ●本次交易未构成关联交易，亦未构成《上市公司重大资产重组管理办法》 规定的重大资产重组。该事项无须提交股东会审议批准。 证券代码：603858 证券简称：步长制药 公告编号：2025-093 山东步长制药股份有限公司 关于拟转让控股子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 ●本次交易实施不存在重大法律障碍。 ●本次交易事项未导致公司合并报表范围发生变化，亦不会对公司财务状况 和经营成果产生重大不利影响。 一、交易概述 为大力发展和整合山东步长制药股份有限公司（以下简称"公司"或"步长 制药"）大健康产业，公司拟将持有的 9 家控股子公司宁波步长贸易有限公司（以 下简称"宁波步长贸易"）、山东步长药妆生物科技有限公司（以下简称"山东 步长药妆"）、山东步长鼎晟药业有限公司（以下简称"山东步长鼎晟"） ...

第五届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）第五届董事会第二十一次 会议的通知于 2025 年 5 月 12 日发出，会议于 2025 年 5 月 19 日下午 13 时以通 讯方式召开，应参会董事 9 人，实参会董事 9 人，会议由董事长赵涛先生主持。 会议出席人数、召开和表决方式符合《中华人民共和国公司法》等法律、法规及 证券代码：603858 证券简称：步长制药 公告编号：2025-091 山东步长制药股份有限公司 《山东步长制药股份有限公司章程》的相关规定，合法有效。 司就 MF59 乳佐剂签署 <委托研发协议> 的议案》 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《关 于拟转让控股子公司股权的公告》（公告编号：2025-093） 表决结果：同意 9 票，反对 0 票，弃权 0 票。 特此公告。 山东步长制药股份有限公司董事会 公司控股子公司浙江天元生物药业有限公司拟与辅必成（上海）医药科技有 限公司 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-092 山东步长制药股份有限公司 关于控股子公司浙江天元与辅必成医药就 MF59 乳佐剂 签署《委托研发协议》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、交易概述 为丰富公司产品研发管线，山东步长制药股份有限公司（以下简称"公司" 或"步长制药"）控股子公司浙江天元生物药业有限公司（以下简称"浙江天元"） 拟与辅必成（上海）医药科技有限公司（以下简称"辅必成医药"）就 MF59 乳 佐剂进行委托研发合作并签署《委托研发协议》。 公司于 2025 年 5 月 19 日召开第五届董事会第二十一次会议，审议通过了《关 于浙江天元生物药业有限公司拟与辅必成（上海）医药科技有限公司就 MF59 乳 佐剂签署<委托研发协议>的议案》。本事项在董事会审批权限范围内，无需提交 股东会审议。 本事项不涉及关联交易，亦不构成《上市公司重大资产重组管理办法》规定 的重大资产重组。 二、交易对方基本情况 （一）基本信息 名称：辅必成（上海）医药科技有限公司 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-093 山东步长制药股份有限公司 关于拟转让控股子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●公司拟将持有的 9 家控股子公司（宁波步长贸易、山东步长药妆、山东步 长鼎晟、山东步长传方、山东步长优品、济南步长驰骋、济南步长财淦、济南步 长瀛玺、济南步长众福）各 1%股权转让给谢继辉。 ●本次交易未构成关联交易，亦未构成《上市公司重大资产重组管理办法》 规定的重大资产重组。该事项无须提交股东会审议批准。 ●本次交易实施不存在重大法律障碍。 ●本次交易事项未导致公司合并报表范围发生变化，亦不会对公司财务状况 和经营成果产生重大不利影响。 （三）公司拟以 0 元人民币将所持有的山东步长鼎晟 1%未实缴部分股权转 让给谢继辉。本次转让完成后，公司持有山东步长鼎晟 94%股权。 （四）公司拟以 0 元人民币将所持有的山东步长传方 1%未实缴部分股权转 让给谢继辉。本次转让完成后，公司持有山东步长传方 93%股权。 （五）公司拟以 0 元 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-091 山东步长制药股份有限公司 第五届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）第五届董事会第二十一次 会议的通知于 2025 年 5 月 12 日发出，会议于 2025 年 5 月 19 日下午 13 时以通 讯方式召开，应参会董事 9 人，实参会董事 9 人，会议由董事长赵涛先生主持。 会议出席人数、召开和表决方式符合《中华人民共和国公司法》等法律、法规及 《山东步长制药股份有限公司章程》的相关规定，合法有效。 经与会董事研究，会议审议通过了如下议案： 1、《关于浙江天元生物药业有限公司拟与辅必成（上海）医药科技有限公 司就 MF59 乳佐剂签署<委托研发协议>的议案》 公司控股子公司浙江天元生物药业有限公司拟与辅必成（上海）医药科技有 限公司就 MF59 乳佐剂进行委托研发合作并签署《委托研发协议》。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn） ...

Core Viewpoint - The company plans to transfer 1% equity stakes in nine subsidiaries to Xie Jihui, which will result in a decrease in the company's shareholding in these subsidiaries by 1% each [1] Group 1: Transaction Details - The subsidiaries involved in the equity transfer include Ningbo Buchang Trading, Shandong Buchang Cosmetics, Shandong Buchang Dingsheng, Shandong Buchang Chuanfang, Shandong Buchang Youpin, Jinan Buchang Chicheng, Jinan Buchang Caigan, Jinan Buchang Yingxi, and Jinan Buchang Zhongfu [1] - The transaction price will be determined through mutual negotiation between the parties involved [1] Group 2: Impact on the Company - Following the completion of the transfer, the company will not have a significant adverse impact on its financial condition and operating results [1] - The transaction does not constitute a related party transaction or a major asset restructuring, and therefore does not require approval from the shareholders' meeting [1]